Proteomic analysis identifies HMGA2 as a novel biomarker of overall survival in papillary renal cell carcinoma
Cancer Medicine · 2023-07 · 12 (13) · 14851-14864
DOI: 10.1002/cam4.6077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 07.06.2023. Verfasst von Tian Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
Although papillary renal cell carcinoma (PRCC) has a relatively favorable prognosis, a small number of patients with lymph node or distant metastasis have a poor prognosis. Owing to the complex typing and heterogeneity of PRCC, it remains difficult to provide risk stratification. The objective of our research was to identify potential markers of PRCC prognosis.
Methods
We performed proteomics and bioinformatics analyses on six pairs of formalin‐fixed paraffin‐embedded tumor and paired normal tissue samples. The Cancer Genome Atlas (TCGA) data were used to analyze the prognostic value of differentially expressed proteins (DEPs) in PRCC. We verified the expression of the major biomarker through immunohistochemistry (IHC) in 91 PRCC tumor specimens.
Results
Proteomic analysis revealed 1544 DEPs between tumor and paired normal tissues. PRCC transcriptomic data from the TCGA database revealed that compared to non‐tumor tissues, the expression of high‐mobility group protein A2 (HMGA2) was upregulated in tumor tissues, and patients with high HMGA2 expression exhibited shorter overall survival times. HMGA2 was associated with PRCC tissue subtype and higher cell pleomorphism. Both TCGA and IHC results showed that HMGA2 expression was associated with lymph node metastasis and clinical stage.
Conclusion
HMGA2 was positively correlated with malignant progression and could be a valuable novel prognostic biomarker for PRCC risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China.
- Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China.
- Department of Pathology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, PR China.
ORCID-Profile: Fen Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wei, T., Xu, H., Liang, H., Lian, Y., Chen, H., Zheng, Z., Zhong, M., Liu, J., Wang, R., & Wang, F. (2023). Proteomic analysis identifies HMGA2 as a novel biomarker of overall survival in papillary renal cell carcinoma. Cancer Medicine, 12(13), 14851-14864. https://doi.org/10.1002/cam4.6077
Vancouver
Wei T, Xu H, Liang H, Lian Y, Chen H, Zheng Z, et al. Proteomic analysis identifies HMGA2 as a novel biomarker of overall survival in papillary renal cell carcinoma. Cancer Medicine. 2023;12(13):14851-14864. doi:10.1002/cam4.6077
BibTeX
@article{Wei2023,
author = {Wei, Tian and Xu, Huiya and Liang, Huishan and Lian, Yating and Chen, Huiyu and Zheng, Zhangyi and Zhong, Minghui and Liu, Junfeng and Wang, Ran and Wang, Fen},
title = {Proteomic analysis identifies HMGA2 as a novel biomarker of overall survival in papillary renal cell carcinoma},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {13},
pages = {14851--14864},
doi = {10.1002/cam4.6077}
}
EUVIMED